FDA Brief

Warning letters Drugs

FDA warning letter to

Applied Therapeutics, Inc.

High riskIssued Dec 3, 2024Posted Dec 3, 2024Center for Drug Evaluation and Research (CDER)

Applied Therapeutics, a trial sponsor, failed to let FDA access deleted electronic trial data and omitted dosing-error information from its drug application.

What happened

FDA inspected Applied Therapeutics as sponsor of a clinical investigation from April 29 to May 3, 2024. FDA found that a third-party vendor deleted Q-global electronic clinical outcome assessment data and audit trails for all 47 subjects two days after FDA preannounced a site inspection, so FDA could not verify the data. FDA also found that the company did not tell FDA in its new drug application about a mislabeled drug concentration that caused at least 19 subjects to receive 80% of the protocol-required dose.

What FDA found

  1. Applied Therapeutics did not let FDA access, copy, and verify records and reports for its clinical investigation, because critical electronic eCOA data and audit trails were deleted and unavailable.

    21 CFR 312.58
  2. Applied Therapeutics did not give FDA a description and analysis of relevant safety and effectiveness information, because it did not disclose dosing errors from a mislabeled drug concentration in its application.

    21 CFR 314.50(d)(5)(iv)

What FDA wants

FDA asks Applied Therapeutics to respond in writing within 15 business days describing actions taken to prevent similar violations and to address the deficiencies, including sufficient details of its corrective action plan.

Who should pay attention

  • clinical trial sponsors and contract research organizations
  • companies using third-party electronic data systems for trials
  • drug applicants submitting clinical study data to FDA

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  4. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk